- Home
- SDHC vs QNCX Comparison
SDHC vs QNCX Comparison
Compare SDHC & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SDHC | QNCX |
|---|---|---|
| Founded | 2008 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 173.0M | 167.0M |
| IPO Year | 2024 | 2019 |
Fundamental Metrics
Financial Performance| Metric | SDHC | QNCX |
|---|---|---|
| Price | $18.02 | $0.15 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 5 | 3 |
| Target Price | ★ $16.70 | $10.00 |
| AVG Volume (30 Days) | 57.7K | ★ 4.7M |
| Earning Date | 03-11-2026 | 03-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $998,173,000.00 | N/A |
| Revenue This Year | $0.58 | N/A |
| Revenue Next Year | $6.61 | N/A |
| P/E Ratio | $84.39 | ★ N/A |
| Revenue Growth | ★ 10.26 | N/A |
| 52 Week Low | $15.00 | $0.14 |
| 52 Week High | $24.75 | $4.55 |
Technical Indicators
Market Signals| Indicator | SDHC | QNCX |
|---|---|---|
| Relative Strength Index (RSI) | 43.23 | 21.15 |
| Support Level | $17.00 | $0.14 |
| Resistance Level | $18.94 | $0.18 |
| Average True Range (ATR) | 1.19 | 0.42 |
| MACD | -0.19 | -0.32 |
| Stochastic Oscillator | 18.82 | 0.17 |
Price Performance
Historical ComparisonAbout SDHC Smith Douglas Homes Corp.
Smith Douglas Homes Corp is a company engaged in the design, construction, and sale of single-family homes in some of the highest growth and desirable markets in the Southeastern United States. It is organized into eight geographical divisions which comprise two reportable segments. Its Southeast segment consists of Atlanta, Central Georgia, Charlotte, Greenville, and Raleigh divisions. Its Central segment consists of Alabama, Houston, and Nashville divisions.
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.